Top Markets
#1 Akedo Akedo +54.88%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.11%
#4 Velvet Velvet +43.34%
#5 Black Phoenix Black Phoenix +34.52%
#6 Ο„emplar Ο„emplar +22.75%
#7 Cross Cross +19.33%
#8 Ribbita by Virtuals Ribbita by Virtuals +16.59%
#9 Bitway Bitway +15.40%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.38%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
E-therapeutics Plc E-therapeutics Plc

E-therapeutics Plc

ETX
Rank in Stocks #38866
E-therapeutics Plc, established in 2001 and headquartered in London, UK, is a... E-therapeutics Plc, established in 2001 and headquartered in London, UK, is a drug discovery research company. It employs an advanced computational platform that conducts in silico screening to forecast compounds and biological targets capable of profoundly altering biological systems, drawing insights from its proprietary network models. Additionally, the firm is developing an RNA interference (RNAi) platform aimed at achieving highly specific gene silencing.
Share Price
$0.12246314
Last synced: 2024-05-08
Market Cap
$767.28K
Change (1 day)
1.50%
Change (1 year)
0.00%
Country
GB
Trade E-therapeutics Plc (ETX)

Category

Healthcare
Revenue for E-therapeutics Plc (ETX)
Revenue in Aug 2026 TTM: 0
According to E-therapeutics Plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for E-therapeutics Plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE